Summary: In a 12-week randomized controlled trial of 50 postmenopausal women with osteopenia, light-to-moderate aerobic walking did not produce a statistically significant between-group difference in bone formation or resorption markers (P1NP, CTX, osteocalcin, total ALP) versus inactive controls (all p>0.05). P1NP and CTX rose in both arms; osteocalcin rose within the exercise arm only, but the between-group comparison remained non-significant. Functional measures (pain, walking speed, balance, activities of daily living) were reported as improved with exercise.
PICO Summary
| Element | Detail |
|---|---|
| Population | 50 postmenopausal women aged 45 to 65 with osteopenia (DXA T-score between -1 and -2.5); prospective, randomized, controlled, single-blind trial; Turkey (NCT06866561). |
| Intervention | Light-to-moderate intensity aerobic walking exercise over 12 weeks (n=25). |
| Comparison | Inactive control group with no structured physical activity plan (n=25). |
| Outcome | No significant between-group difference in bone turnover markers at 12 weeks: P1NP, CTX, osteocalcin and total ALP all p>0.05 versus control. P1NP and CTX increased in both groups from baseline; osteocalcin increased significantly within the exercise group only (within-group p<0.05) but not between groups. Functional outcomes (pain, walking speed, balance, lower-extremity dynamic balance, activities of daily living) were reported as improved with exercise; the abstract provides no between-group effect sizes, 95% CIs or p-values for these, so no ARR/NNT can be derived. No adverse events reported. |
Expert Commentary
This small single-blind randomized trial is best read as a negative biomarker study with a positive functional narrative. For its stated primary aim, examining whether light-to-moderate aerobic walking shifts rapidly responsive bone formation and resorption markers, the answer is no: P1NP, CTX, osteocalcin and total alkaline phosphatase showed no significant between-group difference at 12 weeks, and P1NP and CTX rose in controls too, which argues against an exercise-specific signal. The within-group rise in osteocalcin in the exercise arm is hypothesis-generating at most and should not be presented as a treatment effect. The headline that is sometimes attached to this study, that walking improves bone turnover, is not supported by the between-group data. The most important limitation is power: with 25 per arm and a 12-week window, the trial is underpowered to detect modest marker changes, and biochemical markers were not paired with repeat DXA, so any structural claim is premature. The reported gains in pain, walking speed, balance and daily function are plausible and clinically attractive, but the abstract supplies no between-group statistics for them, so they remain descriptive. Can I use this with my patients? Yes, but honestly: recommend walking to postmenopausal women with osteopenia for mobility, balance and fall-relevant function, not as a proven way to move bone markers. Larger, longer, DXA-anchored trials are needed before stronger claims are warranted.
References
Deniz KN, Aksoy MK. The effect of aerobic exercise on bone formation and resorption markers and the quality of life tests in postmenopausal osteopenic patients. BMC Musculoskelet Disord. 2025;26(1):385. doi:10.1186/s12891-025-08578-z
